Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure

DOI Web Site 被引用文献1件
  • Prateeti Khazanie
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Bradley G. Hammill
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Laura G. Qualls
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Gregg C. Fonarow
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Stephen C. Hammill
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Paul A. Heidenreich
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Sana M. Al-Khatib
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Jonathan P. Piccini
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Frederick A. Masoudi
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Pamela N. Peterson
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Jeptha P. Curtis
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Adrian F. Hernandez
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...
  • Lesley H. Curtis
    From the Duke Clinical Research Institute (P.K., B.G.H., L.G.Q., S.M.A.-K., J.P.P., A.F.H., L.H.C.) and Department of Medicine (P.K., S.M.A.-K., J.P.P., A.F.H., L.H.C.), Duke University School of Medicine, Durham, NC; Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles (G.C.F.); Department of Medicine, University of Colorado, Aurora (F.A.M., P.N.P.); Department of Medicine, Denver Health Medical Center, CO (P.N.P.); Department of Medicine, Mayo Clinic, Rochester, MN (S.C.H.);...

書誌事項

タイトル別名
  • Analysis of the ICD Registry and ADHERE

説明

<jats:sec> <jats:title>Background—</jats:title> <jats:p>Cardiac resynchronization therapy with defibrillator (CRT-D) reduces morbidity and mortality among selected patients with heart failure in clinical trials. The effectiveness of this therapy in clinical practice has not been well studied.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods and Results—</jats:title> <jats:p> We compared a cohort of 4471 patients from the National Cardiovascular Data Registry’s Implantable Cardioverter-Defibrillator (ICD) Registry hospitalized primarily for heart failure and who received CRT-D between April 1, 2006, and December 31, 2009, to a historical control cohort of 4888 patients with heart failure without CRT-D from the Acute Decompensated Heart Failure National Registry (ADHERE) hospitalized between January 1, 2002, and March 31, 2006. Both registries were linked with Medicare claims to evaluate longitudinal outcomes. We included patients from the ICD Registry with left ventricular ejection fraction ≤35% and QRS duration ≥120 ms who were admitted for heart failure. We used Cox proportional hazards models to compare outcomes with and without CRT-D after adjustment for important covariates. After multivariable adjustment, CRT-D was associated with lower 3-year risks of death (hazard ratio, 0.52; 95% confidence interval, 0.48–0.56; <jats:italic>P</jats:italic> <0.001), all-cause readmission (hazard ratio, 0.69; 95% confidence interval, 0.65–0.73; <jats:italic>P</jats:italic> <0.001), and cardiovascular readmission (hazard ratio, 0.60; 95% confidence interval, 0.56–0.64; <jats:italic>P</jats:italic> <0.001). The association of CRT-D with mortality did not vary significantly among subgroups defined by age, sex, race, QRS duration, and optimal medical therapy. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p>CRT-D was associated with lower risks of mortality, all-cause readmission, and cardiovascular readmission than medical therapy alone among patients with heart failure in community practice.</jats:p> </jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ